New drug and better measurement tools aim to tackle severe valley fever

NCT ID NCT07712484

Not yet recruiting Disease control Sponsor: F2G Ltd Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This phase 2 trial tests an experimental antifungal drug called olorofim in people with a severe, body-wide form of Valley Fever (disseminated coccidioidomycosis) that has not responded to standard treatments. The study also evaluates new questionnaires about symptoms and quality of life to see if they are useful for measuring how well treatments work. Participants receive either olorofim or a placebo, both added to their usual care, for 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental antifungal drug called olorofim
What this could lead to: If successful, this trial could help establish better ways to measure treatment effectiveness for disseminated Valley Fever, potentially leading to improved therapies.
What could go wrong: This is a small, early-phase trial focused on testing measurement tools, not on proving the drug works. The drug may not show clear benefit, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates